Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Cvs Group Plc LSE:CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.00 0.65% 2,325.00 2,320.00 2,330.00 2,340.00 2,280.00 2,320.00 382,666 16:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 427.8 9.9 8.1 287.0 1,644

Cvs Share Discussion Threads

Showing 526 to 545 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
31/1/2019
16:58
Encouraging to see CEO’s and Finance directors wives buying shares along with the chairman.
kemorkid
30/1/2019
09:50
Yes I have just cut and run. With brexit as well the pool of vets wanting to come from overseas will be less going forward which will drive salaries higher I would assume, I cannot imagine this improving anytime soon.
mccookie
30/1/2019
09:42
Sometimes it's better to take the loss than take a bigger one further down the road.
bulltradept
30/1/2019
09:37
I’d have to agree with the above- the statement more or less says our costs in particular payroll are increasing at a greater rate than our sales, however are still focussed on aquisitions. If sales growth is driven by aquistitions that would suggest the vet businesses taken over by CVS are declining year on year significantly and the aquisition pipelines is propping the sales number up. Hopefully they get taken over and I can recover my losses!!!
mccookie
30/1/2019
09:26
These shares have cost me a fortune! The downward trend is very worrying.
mccookie
29/1/2019
17:34
Https://www.investorschampion.com/channel/blog/cvs-is-in-need-of-treatment
waldron
29/1/2019
11:57
Another victim of Brexit. Still cash-generative, just going to hang on for a turnaround or a takeover now. :-(
runthejoules
29/1/2019
09:59
RNS Number : 3337O CVS Group plc 29 January 2019 29 January 2019 CVS Group plc ("CVS" or the "Group") Trading Update CVS, the integrated veterinary services group, provides the following update on headline trading in respect of the financial half year ended 31 December 2018 (H1 2019). H1 2019 Performance In H1 2019, the Group's total sales increased by 23.7% and like for like sales ("LFL")(1) increased by 4.0% both compared to the financial half year ended 31 December 2017 (H1 2018). Within the Practices Division, sales have increased by 23.9% and like-for-like sales have increased by 3.2% compared to H1 2018. In addition, Laboratory Division sales increased by 6.3%, Crematoria Division sales increased by 11.3% and Animed Direct sales increased by 16.2% compared to H1 2018. Gross margins(2) for the Group in H1 2019 were 76.2% compared to 79.5% in H1 2018. This reduction is entirely due to an increased mix of Farm business for which margins are lower. Sales from Farm practices now represent 8.9% of group sales in H1 2019 compared to 3.2% in H1 2018. Gross margins in our small animal practices have increased to 81.3% in H1 2019 compared to 80.9% in H1 2018. As a result of a number of actions taken, CVS continues to see a gradual improvement in clinical vacancy rates for both vets and nurses compared to the start of the financial year. However, as previously highlighted the Group remains heavily reliant on locum cover given the continuing industry-wide shortage of vets. Consequently, employment costs in H1 2019 are well above H1 2018 due to the increase in sales as noted above, combined with above inflation salary increases and a significant increase in market rates for locums. Over the past two years, CVS has acquired 24 practices in The Netherlands and has diversified into Farm and Equine practices. Early performance from these newer divisions has been disappointing with financial results falling short of our expectations. In all these divisions, financial performance has been adversely impacted by the poor support of pharmaceutical companies and we continue to push for transparent and appropriate pricing. In light of the above and certain other cost increases, the Group expects to announce EBITDA(3) for H1 2019 that is broadly flat compared to H1 2018. As at 31 December 2018, CVS had net debt of GBP116.8m and bank covenant leverage(4) of 2.4x. The Group remains comfortably within its covenants and continues to generate positive operating cashflow. Outlook Given the financial performance in H1 2019, CVS now expects full year EBITDA to be materially below current market expectations. A number of cost savings have been identified across the Group and these are expected to generate savings both in H2 2019 and in the remainder of calendar year 2019, with ongoing effect thereafter. In conjunction with cost savings, additional procedures have been implemented over the employment of locums in practices and the Group expects to see a reduction in locum costs in the remainder of the financial year as a result. Acquisitions Further to the Trading Update issued on 29 November 2018, the Group completed the acquisition of three further practices in the first week of December 2018, for combined consideration of GBP5.0m. No further acquisitions have been made since that time. The Group believes that acquisition multiples being sought by practice owners are increasingly above levels which will deliver acceptable financial returns. Whilst the group has a further pipeline of acquisitions, for which terms have been agreed in principle, the Board is re-evaluating all acquisitions and particularly the multiples it is willing to pay. Interim Results The Group expects to announce its interim results, for the six months ended 31 December 2018, on 29 March 2019.
florenceorbis
04/12/2018
10:05
Looking good entry point
kemorkid
04/12/2018
09:53
Now Goldman Sachs in for 6%....
lomax99
03/12/2018
10:10
Good to see Echo Street Capital Management take a decent stake.
lomax99
30/11/2018
05:56
I'm working in the pet industry as such, when older vets retire, they generally sell out to cooperates, CVS being very popular, the fact they bought the neighboring large animal practise near me a few years ago and continued to stay open surprised me from the rural farm vet staffing shortage, they have a model that works. It's harder for individual to take over practises due to financial and staffing issues, we as a nation of pet lovers, cannot get away from the emotional substitutes that our pets become when we have less family and other human companionship. If the finances stay true then this seems a long term safe investment
p winky
29/11/2018
13:43
The effects of both the new Lucy's Law and the Animal Welfare regulations kicking in is going to mean a massive decline of the amount of puppies allowed to be bred. Consequently Clients of CVSG Vet Practices are going to have a lot of Clients who can no longer afford to buy or even find a puppy to purchase. Over time this must mean a lot less dogs to be treated by Vets.
the dogsbody
29/11/2018
13:21
Shares magazine today: CVS warns on margins as staffing costs soar Shares in veterinary services group CVS (CVSG:AIM) slump 13.2% to 630.5p on the disappointing news soaring rates for temporary veterinary staff and other rising costs are hurting its margins. CVS says earnings before interest, tax, depreciation and amortisation (EBITDA) margins will be lower than last year as it is relying more on temporary staff despite lower vacancy rates. Unfortunately for CVS, skilled and temporary veterinary surgeons come at a high price. Day veterinary locum rates are currently 14% above the same period last year. STRONG GROWTH IN VETERINARY PRACTICES The good news is all divisions are delivering growth in revenues with overall like-for-like sales climbing 4.7% in the four months to 31 October compared to the same period of 2017. In the company’s biggest division representing nearly 90% of sales, Veterinary Practices, like-for-sales grew 3.8%. The Healthy Pet Club continues to attract new members keen to take advantage of loyalty benefits, regular health checks and discounts on pharmaceutical products. IS CVS A POTENTIAL TAKEOVER TARGET? Acquisitions are a key part of CVS' growth strategy and several more are expected to complete over the next couple of months as the company consolidates a fragmented industry, although persisting share price weakness could stoke speculation that CVS itself may become a takeover target. Here in August, we considered whether the long-term predator could become prey, noting that Whiskas pet food owner Mars Petcare had acquired UK services group Linnaeus and BC Partners had bought VetPartners.
lomax99
29/11/2018
11:09
So happy directors managed to sell at 910 only a few weeks ago.
wilsonst1
29/11/2018
08:41
That's a profits warning
tsmith2
29/11/2018
08:17
It does appear that the market reads it as a profit warning.
rafieh
29/11/2018
07:55
Priced in? - who knows, would have thought so. A bite sized chunk for someone?
lomax99
29/11/2018
07:53
Undoubtedly, as they only ever tend to focus on any negatives. No need to focus on any positives - lfl sales growth, improving performance of recent acquisitions, strong pace of acquisition, healthy pipeline, ongoing/recent initiatives to improve retention and recruitment, etc.
lomax99
29/11/2018
07:52
Recent dropped priced in?
p winky
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
CVSG
Cvs
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210506 02:39:26